SHANGHAI, Nov. 9 /PRNewswire-Asia/ -- The pharma and biotech sectors are at a pivotal point in their evolution. The companies are facing significant pressure to change with thinning pipelines, skyrocketing R&D costs, calls for lower prices and a greater regulatory burden, these conditions together with the financial crisis have made the work of creating new drugs harder than ever. Big pharmaceutical companies are being forced to globalize their R&D operations, especially to emerging markets.
Under this background, leaders of pharma and biotech companies from around the world will gather in Shanghai on March 4-5, 2010 at Asia Pharma R&D Leaders 2010 for strategies to capitalize on the enormous opportunity the booming Asia Market provides.
This event focuses on the operational, regulatory, and strategic challenges of outsourcing your drug discovery work to Asia.
Hear from distinguished industry experts at Asia Pharma R&D Leaders 2010. Some of this year's highlighted topics include:
-- Partnering for innovation in Asia, new collaboration opportunities with big pharma -- Laurent Bertin, Vice President, R&D External Innovation, Sanofi- Aventis -- Hans-Jochiam Bohm, Head of Global Chemistry, Hoffman La-Roche -- Daniel Grant, Head of Strategic Alliances, Pfizer Australia -- Pierre Desmons, Director, Head of Development Partnerships, GlaxoSmithKline Biologicals -- Regulatory updates in China and how FDA is making sure the quality of outsourced work -- Christopher Hickey, Country Director (China), U.S. Food and Drug Administration -- Successful stories of R&D operation management in Asia and Do's & Don'ts in outsourcing -- Steve Yang, Head of Research Asia Global R&D, Pfizer -- Lily Lee, Senior Vice President and Head of Pharmaceutical R&D Asia,
|SOURCE Global Leaders Institute|
Copyright©2009 PR Newswire.
All rights reserved